The Claim
Semaglutide use is associated with a reduction in diabetes risk that becomes detectable only after six months of continuous treatment, indicating a gradual development of metabolic benefit relative to liraglutide.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People taking semaglutide for six months or longer show a lower risk of developing diabetes compared to those taking liraglutide, and this difference does not appear earlier than six months.
See the scientific wording
The association between semaglutide use and reduced diabetes risk emerges only after six months of treatment, suggesting that the metabolic benefit of semaglutide relative to liraglutide develops gradually and is not immediate.
Over time, the drug keeps the GLP-1 receptor active, which slowly improves the pancreas's ability to release insulin when needed and helps the body use insulin more effectively, reducing blood sugar levels enough to prevent diabetes after six months.
What the research says
1 studyThis study found that semaglutide and liraglutide work about the same for the first six months in preventing diabetes, but after six months, semaglutide starts doing significantly better — showing its full benefit takes time to show up.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.